BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nkongolo S, Hollnberger J, Urban S. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35028672 DOI: 10.1007/s00103-022-03486-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Herta T, Hahn M, Maier M, Fischer J, Niemeyer J, Hönemann M, Böhlig A, Gerhardt F, Schindler A, Schumacher J, Berg T, Wiegand J, van Bömmel F. Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection. Pathogens 2022;11:517. [DOI: 10.3390/pathogens11050517] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]